ELMD

AI Memo

Electromed

As of 2026-08-28/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Mixed Q4/FY2026 print has triggered a post-earnings reset • 2026-08-27

Base target: $34 / p=50% prob

Biggest risk

The market reaction indicates that strong EPS and margin performance did not offset the modest revenue miss, hospital-channel decline, low forward visibility, and announced CEO transition. New-representative ramp costs, reimbursement dynamics, and single-product concentration remain material execution risks. No reliable post-print analyst target or estimate-revision set is available.

Invalidation

Break below $23 or thesis failure.

What would change my mind?

FY2026 showed record revenue and profit, 15 consecutive quarters of year-over-year growth, improving operating leverage, strong gross margins, $20.5 million of cash, and no debt. Continued homecare growth, sales-representative productivity, payer coverage, and bronchiectasis-market development could support recovery from the recent selloff.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-28

Base target

$34

p=50%

Bull target

$42

p=20%

Bear target

$23

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Hospital-channel weakness and single-product concentration may continue to pressure sentiment
Homecare execution and bronchiectasis penetration remain the core upside path
FY2026 showed record revenue and profit, 15 consecutive quarters of year-over-year growth, improving operating leverage, strong gross margins, $20.5 million of cash, and no debt.

BearKey bullets

CEO succession and leadership-continuity risk by April 2027
Hospital revenue volatility and long sales cycles
Low analyst coverage and limited post-earnings revision visibility

WatchKey bullets

Mixed Q4/FY2026 print has triggered a post-earnings reset

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $34 (p=50%)

Target spread vs base: +24% / -32%

Scenario probabilities

Bull Target: $42 (p=20%)Base Target: $34 (p=50%)Bear Target: $23 (p=30%)

Commentary

Primary company evidence remains operationally strong, but the post-earnings narrative is mixed: record results and management’s long-term growth case were offset by hospital weakness, a slight reported revenue miss versus consensus, CEO succession risk, and a sharp decline to the August 27 anchor price of $30.14. Coverage is thin, social data and options data are unavailable, and analyst revisions are not established. The appropriate stance is cautious monitoring rather than a high-conviction bullish call.

As of 2026-08-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Hospital-channel weakness and single-product concentration may continue to pressure sentiment
Homecare execution and bronchiectasis penetration remain the core upside path

Scenarios

Bull Target (Scenario probability)

$42 / p=20% prob

Base Target (Scenario probability)

$34 / p=50% prob

Bear Target (Scenario probability)

$23 / p=30% prob

Analysis 2026-08-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-27
Mixed Q4/FY2026 print has triggered a post-earnings reset
Electromed reported record Q4 revenue of $19.4 million, operating income of $3.8 million, diluted EPS of $0.39, and its 15th consecutive quarter of year-over-year revenue and profit growth. However, trusted post-print coverage reported a slight revenue miss versus consensus and a negative share reaction. The SEC filing also disclosed the planned CEO retirement.[#SEC-8K-2026-08-25]
Prob 100.00% • Move -18.00% • Priced-in 100.00%
EVENT2027-04-02
CEO succession becomes a defined execution checkpoint
CEO Jim Cunniff expects to retire on or about April 2, 2027, and the board has begun a national search with an executive search firm. The transition could be orderly, but the timing creates continuity and execution risk while the company is investing ahead of territory expansion.[#SEC-8K-2026-08-25]
Prob 70.00% • Move -7.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Hospital-channel weakness and single-product concentration may continue to pressure sentiment
2026-09-30
Hospital revenue declined 29% in Q4, while management characterized hospital orders as longer-cycle and less predictable. ELMD remains a low-coverage, concentrated small-cap medtech issuer, so another weak hospital or prescription-conversion update could extend the recent repricing.
Prob 55% • Move -12% • Priced-in 65%

Long-term Catalysts

Months to a year

Homecare execution and bronchiectasis penetration remain the core upside path
2027-06-30
Q4 direct homecare revenue rose 15.2%, FY2026 homecare revenue rose 16.3%, and annualized revenue per weighted-average homecare representative exceeded the company target range. The investor presentation highlights a large underpenetrated bronchiectasis market, continued sales-force expansion, payer contracting, and market development as durable growth drivers.[#SEC-8K-2026-08-25]
Prob 55% • Move 20% • Priced-in 45%

Risks

CEO succession and leadership-continuity risk by April 2027
Hospital revenue volatility and long sales cycles
Low analyst coverage and limited post-earnings revision visibility
Recent insider open-market sales are a sentiment monitor, not evidence of operating deterioration.[#SEC-FORM4-2026-06-09]
Reimbursement and payer-mix changes, including Medicare exposure
Sales-force expansion may temporarily dilute productivity
Single-product and concentrated-market risk

Peers

Symbol	Summary
BSX	Boston Scientific is a much larger, diversified medtech benchmark with deeper distribution; the comparison highlights ELMD’s smaller scale and greater execution sensitivity rather than proving a direct valuation premium.
EW	Edwards Lifesciences is an adjacent high-quality device benchmark, but its scale, diversification, and coverage make it a loose comp for ELMD’s single-product airway-clearance model.
OFIX	Orthofix is a closer small-cap device-size reference, though not a direct airway-clearance peer; it mainly underscores the volatility associated with smaller medtech commercialization stories.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-28

Loading AI feed…

Symbol

Summary

BSX

Boston Scientific is a much larger, diversified medtech benchmark with deeper distribution; the comparison highlights ELMD’s smaller scale and greater execution sensitivity rather than proving a direct valuation premium.

Edwards Lifesciences is an adjacent high-quality device benchmark, but its scale, diversification, and coverage make it a loose comp for ELMD’s single-product airway-clearance model.

OFIX

Orthofix is a closer small-cap device-size reference, though not a direct airway-clearance peer; it mainly underscores the volatility associated with smaller medtech commercialization stories.